[1]
|
Krammer, F., Smith, G.J.D., Fouchier, R.A.M., Peiris, M., Kedzierska, K., Doherty, P.C., et al. (2018) Influenza. Nature Reviews Disease Primers, 4, Article No. 3. https://doi.org/10.1038/s41572-018-0002-y
|
[2]
|
Burnet, F.M. (1979) Portraits of Viruses: Influenza Virus A. Intervirology, 11, 201-214.
https://doi.org/10.1159/000149035
|
[3]
|
李驰, 冯靖. 基于血凝素的新型流感疫苗的研究进展[J]. 中国生物制品学杂志, 2014, 27(2): 272-279.
|
[4]
|
Gaitonde, D.Y., Moore, F.C. and Morgan, M.K. (2019) Influenza: Diagnosis and Treatment. American Family Physician, 100, 751-758.
|
[5]
|
Taubenberger, J.K. and Morens, D.M. (2006) 1918 Influ-enza: The Mother of All Pandemics. Emerging Infectious Diseases, 12, 15-22. https://doi.org/10.3201/eid1209.05-0979
|
[6]
|
Paget, J., Caini, S., Del Riccio, M., van Waarden, W. and Meijer, A. (2022) Has Influenza B/Yamagata Become Extinct and What Implications Might This Have for Quadrivalent Influenza Vaccines? Eurosurveillance, 27, Article ID: 2200753. https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200753
|
[7]
|
Sederdahl, B.K. and Williams, J.V. (2020) Epi-demiology and Clinical Characteristics of Influenza C Virus. Viruses, 12, Article No. 89. https://doi.org/10.3390/v12010089
|
[8]
|
中华预防医学会流感疫苗保护效果真实世界研究共识专家组. 流行性感冒疫苗保护效果真实世界研究专家共识[J]. 中国疫苗和免疫, 2022, 28(6): 617-637.
|
[9]
|
Plotkin, J.B., Dush-off, J. and Levin, S.A. (2002) Hemagglutinin Sequence Clusters and the Antigenic Evolution of Influenza A Virus. Pro-ceedings of the National Academy of Sciences of the United States of America, 99, 6263-6268.
https://doi.org/10.1073/pnas.082110799
|
[10]
|
Smith, D.J., Lapedes, A.S., de Jong, J.C., Bestebroer, T.M., Rim-melzwaan, G.F., Osterhaus, A.D., et al. (2004) Mapping the Antigenic and Genetic Evolution of Influenza Virus. Science, 305, 371-376.
https://doi.org/10.1126/science.1097211
|
[11]
|
Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., et al. (2013) Cellular Immune Correlates of Protection against Symptomatic Pandemic Influenza. Nature Medicine, 19, 1305-1312.
https://doi.org/10.1038/nm.3350
|
[12]
|
Wang, Z., Wan, Y., Qiu, C., Quiñones-Parra, S., Zhu, Z., Loh, L., et al. (2015) Recovery from Severe H7N9 Disease Is Associated with Diverse Response Mechanisms Dominated by CD8⁺ T Cells. Nature Communications, 6, Article No. 6833. https://doi.org/10.1038/ncomms7833
|
[13]
|
Hayward, A.C., Wang, L., Goonetilleke, N., Fragaszy, E.B., Bermingham, A., Copas, A., et al. (2015) Natural T Cell-Mediated Protec-tion against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine, 191, 1422-1431. https://doi.org/10.1164/rccm.201411-1988OC
|
[14]
|
Valkenburg, S.A., Gras, S., Guillonneau, C., La Gruta, N.L., Thomas, P.G., Purcell, A.W., et al. (2010) Protective Efficacy of Cross-Reactive CD8+ T Cells Recognising Mutant Viral Epitopes Depends on Peptide-MHC-I Structural Interactions and T Cell Activation Threshold. PLOS Pathogens, 6, e1001039.
https://doi.org/10.1371/journal.ppat.1001039
|
[15]
|
Grant, E.J., Josephs, T.M., Valkenburg, S.A., Wooldridge, L., Hellard, M., Rossjohn, J., et al. (2016) Lack of Heterologous Cross-Reactivity toward HLA-A*02:01 Restricted Viral Epitopes Is Underpinned by Distinct αβT Cell Receptor Signatures. Journal of Biological Chemistry, 291, 24335-24351. https://doi.org/10.1074/jbc.M116.753988
|
[16]
|
Quiñones-Parra, S.M., Clemens, E.B., Wang, Z., Croom, H.A., Kedzierski, L., McVernon, J., et al. (2016) A Role of Influenza Virus Exposure History in Determining Pandemic Sus-ceptibility and CD8+ T Cell Responses. Journal of Virology, 90, 6936-6947. https://doi.org/10.1128/JVI.00349-16
|
[17]
|
Gerhard, W., Mozdzanowska, K. and Zharikova, D. (2006) Prospects for Universal Influenza Virus Vaccine. Emerging Infectious Diseases, 12, 569-574. https://doi.org/10.3201/eid1204.051020
|
[18]
|
Grebe, K.M., Yewdell, J.W. and Bennink, J.R. (2008) Heterosubtypic Immunity to Influenza A Virus: Where Do We Stand? Microbes and Infection, 10, 1024-1029. https://doi.org/10.1016/j.micinf.2008.07.002
|
[19]
|
Koutsakos, M., Illing, P.T., Nguyen, T.H.O., Mifsud, N.A., Crawford, J.C., Rizzetto, S., et al. (2019) Human CD8+ T Cell Cross-Reactivity across Influenza A, B and C Viruses. Nature Immunology, 20, 613-625.
https://doi.org/10.1038/s41590-019-0320-6
|
[20]
|
van de Sandt, C.E., Hillaire, M.L., Geelhoed-Mieras, M.M., Os-terhaus, A.D., Fouchier, R.A. and Rimmelzwaan, G.F. (2015) Human Influenza A Virus-Specific CD8+ T-Cell Re-sponse Is Long-Lived. The Journal of Infectious Diseases, 212, 81-85. https://doi.org/10.1093/infdis/jiv018
|
[21]
|
Rimmelzwaan, G.F., Fouchier, R.A. and Osterhaus, A.D. (2007) Influ-enza Virus-Specific Cytotoxic T Lymphocytes: A Correlate of Protection and a Basis for Vaccine Development. Current Opinion in Biotechnology, 18, 529-536.
https://doi.org/10.1016/j.copbio.2007.11.002
|
[22]
|
Gras, S., Kedzierski, L., Valkenburg, S.A., Laurie, K., Liu, Y.C., Denholm, J.T., et al. (2010) Cross-Reactive CD8+ T-Cell Immunity between the Pandemic H1N1-2009 and H1N1-1918 Influenza A Viruses. Proceedings of the National Academy of Sciences of the United States of America, 107, 12599-12604. https://doi.org/10.1073/pnas.1007270107
|
[23]
|
Cruz, F.M., Colbert, J.D., Merino, E., Kriegsman, B.A. and Rock, K.L. (2017) The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules. Annual Review of Immunology, 35, 149-176.
https://doi.org/10.1146/annurev-immunol-041015-055254
|
[24]
|
Trapani, J.A. and Smyth, M.J. (2002) Functional Significance of the Perforin/Granzyme Cell Death Pathway. Nature Reviews Immunology, 2, 735-747. https://doi.org/10.1038/nri911
|
[25]
|
Price, G.E., Huang, L., Ou, R., Zhang, M. and Moskophidis, D. (2005) Per-forin and Fas Cytolytic Pathways Coordinately Shape the Selection and Diversity of CD8+-T-Cell Escape Variants of In-fluenza Virus. Journal of Virology, 79, 8545-8559. https://doi.org/10.1128/JVI.79.13.8545-8559.2005
|
[26]
|
Laidlaw, B.J., Craft, J.E. and Kaech, S.M. (2016) The Multifaceted Role of CD4+ T Cells in CD8+ T Cell Memory. Nature Reviews Immunology, 16, 102-111. https://doi.org/10.1038/nri.2015.10
|
[27]
|
Lopez, C.E. and Legge, K.L. (2020) Influenza A Virus Vaccination: Im-munity, Protection, and Recent Advances toward a Universal Vaccine. Vaccines (Basel), 8, Article No. 434. https://doi.org/10.3390/vaccines8030434
|
[28]
|
Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., et al. (2022) SARS-CoV-2 Vaccination Induces Immunological T Cell Memory Able to Cross-Recognize Variants from Alpha to Omicron. Cell, 185, 847-859.e11.
https://doi.org/10.1016/j.cell.2022.01.015
|
[29]
|
Weinfurter, J.T., Brunner, K., Capuano, S.V., Li, C., Broman, K.W., Kawaoka, Y., et al. (2011) Cross-Reactive T Cells Are Involved in Rapid Clearance of 2009 Pandemic H1N1 Influenza Virus in Nonhuman Primates. PLOS Pathogens, 7, e1002381. https://doi.org/10.1371/journal.ppat.1002381
|
[30]
|
Olukitibi, T.A., Ao, Z., Azizi, H., Mahmoudi, M., Coombs, K., Kobasa, D., et al. (2022) Development and Characterization of Influenza M2 Ectodomain and/or Hemagglutinin Stalk-Based Dendritic Cell-Targeting Vaccines. Frontiers in Microbiology, 13, Article ID: 937192. https://doi.org/10.3389/fmicb.2022.937192
|
[31]
|
Sette, A., Newman, M., Livingston, B., McKinney, D., Sidney, J., Ishioka, G., et al. (2002) Optimizing Vaccine Design for Cellular Processing, MHC Binding and TCR Recognition. Tis-sue Antigens, 59, 443-451.
https://doi.org/10.1034/j.1399-0039.2002.590601.x
|
[32]
|
Di Carluccio, A.R., Triffon, C.F. and Chen, W. (2018) Perpetual Complexity: Predicting Human CD8+ T-Cell Responses to Pathogenic Peptides. Immunology & Cell Biology, 96, 358-369. https://doi.org/10.1111/imcb.12019
|
[33]
|
Dönnes, P. and Elofsson, A. (2002) Prediction of MHC Class I Binding Peptides, Using SVMHC. BMC Bioinformatics, 3, Article No. 25. https://doi.org/10.1186/1471-2105-3-25
|
[34]
|
Andreatta, M. and Nielsen, M. (2016) Gapped Sequence Alignment Using Artificial Neural Networks: Application to the MHC Class I System. Bioinformatics, 32, 511-517. https://doi.org/10.1093/bioinformatics/btv639
|
[35]
|
Vita, R., Mahajan, S., Overton, J.A., Dhanda, S.K., Martini, S., Cantrell, J.R., et al. (2019) The Immune Epitope Database (IEDB): 2018 Update. Nucleic Acids Research, 47, D339-D343. https://doi.org/10.1093/nar/gky1006
|
[36]
|
张磊, 严嘉玲, 马茜. 多肽疫苗研究进展[J]. 中国疫苗和免疫, 2023, 29(2): 231-238.
|
[37]
|
Abbasi, J. (2021) Broad and Durable Antibody Response in Universal Flu Vaccine Trial. JAMA, 325, 121.
https://doi.org/10.1001/jama.2020.25670
|
[38]
|
Oftung, F., Næss, L.M., Laake, I., Stoloff, G. and Pleguezuelos, O. (2022) FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN-γ and Granzyme B ELISpot Assay. Vaccines (Basel), 10, Article No. 1528. https://doi.org/10.3390/vaccines10091528
|
[39]
|
Pleguezuelos, O., Dille, J., de Groen, S., Oftung, F., Niesters, H.G.M., Islam, M.A., et al. (2020) Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial. Annals of Internal Medicine, 172, 453-462. https://doi.org/10.7326/M19-0735
|
[40]
|
赵淑敏, 陈继军. 通用流感疫苗研究进展[J]. 微生物学免疫学进展, 2023, 51(2): 60-68.
|
[41]
|
Francis, J.N., Bunce, C.J., Horlock, C., Watson, J.M., Warrington, S.J., Georges, B., et al. (2015) A Novel Peptide-Based Pan-Influenza A Vaccine: A Double Blind, Randomised Clinical Trial of Immunogenicity and Safety. Vaccine, 33, 396-402. https://doi.org/10.1016/j.vaccine.2014.06.006
|
[42]
|
Atmar, R.L., Bernstein, D.I., Winokur, P., Frey, S.E., Angelo, L.S., Bryant, C., et al. (2023) Safety and Immunogenicity of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Inactivated Influenza Vaccine in Young Adults—A Randomized Clinical Trial. Vac-cine, 41, 2716-2722. https://doi.org/10.1016/j.vaccine.2023.03.023
|
[43]
|
Atsmon, J., Caraco, Y., Ziv-Sefer, S., Shaikevich, D., Abramov, E., Volokhov, I., et al. (2014) Priming by a Novel Universal Influenza Vaccine (Multimer-ic-001)—A Gateway for Improving Immune Response in the Elderly Population. Vaccine, 32, 5816-5823. https://doi.org/10.1016/j.vaccine.2014.08.031
|
[44]
|
Lowell, G.H., Ziv, S., Bruzil, S., Babecoff, R. and Ben-Yedidia, T. (2017) Back to the Future: Immunization with M-001 Prior to Trivalent Influenza Vaccine in 2011/12 Enhanced Pro-tective Immune Responses against 2014/15 Epidemic Strain. Vaccine, 35, 713-715. https://doi.org/10.1016/j.vaccine.2016.12.063
|
[45]
|
Dorrell, L., Yang, H., Iversen, A.K., Conlon, C., Suttill, A., Lancaster, M., et al. (2005) Therapeutic Immunization of Highly Active Antiretroviral Therapy-Treated HIV-1-Infected Patients: Safety and Immunogenicity of an HIV-1 Gag/Poly-Epitope DNA Vaccine. Aids, 19, 1321-1323. https://doi.org/10.1097/01.aids.0000180104.65640.16
|
[46]
|
Berthoud, T.K., Hamill, M., Lillie, P.J., Hwenda, L., Collins, K.A., Ewer, K.J., et al. (2011) Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic In-fluenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 52, 1-7. https://doi.org/10.1093/cid/ciq015
|
[47]
|
Evans, T.G., Bussey, L., Eagling-Vose, E., Rutkowski, K., Ellis, C., Argent, C., et al. (2022) Efficacy and Safety of a Universal Influenza A Vaccine (MVA-NP+M1) in Adults When Given after Seasonal Quadrivalent Influenza Vaccine Immunisation (FLU009): A Phase 2b, Randomised, Double-Blind Trial. The Lancet Infectious Diseases, 22, 857-866.
https://doi.org/10.1016/S1473-3099(21)00702-7
|
[48]
|
Puksuriwong, S., Ahmed, M.S., Sharma, R., Krishnan, M., Leong, S., Lambe, T., et al. (2020) Modified Vaccinia Ankara-Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Naso-pharynx-Associated Lymphoid Tissue. The Journal of Infectious Diseases, 222, 807-819. https://doi.org/10.1093/infdis/jiz593
|
[49]
|
Guilfoyle, K., Major, D., Skeldon, S., James, H., Tingstedt, J.L., Polacek, C., et al. (2021) Protective Efficacy of a Polyvalent Influenza A DNA Vaccine against both Homologous (H1N1pdm09) and Heterologous (H5N1) Challenge in the Ferret Model. Vaccine, 39, 4903-4913. https://doi.org/10.1016/j.vaccine.2020.09.062
|